

[illegible]

- *Johns + Adams*

biodegradable polymer, a mixture of biodegradable and non-biodegradable polymers, and a copolymer comprising biodegradable and non-biodegradable units.

10. The pharmaceutical formulation of Claim 6, wherein the polymeric matrix comprises a polymer selected from the group consisting of blocked polymers, unblocked polymers, and mixtures thereof.

11. The pharmaceutical formulation of Claim 6, wherein the polymeric matrix comprises a polymer selected from the group consisting of a poly(glycolide); a poly(lactide-co-glycolide); a poly(lactic acid); a poly(glycolic acid); a poly(lactic acid-co-glycolic acid); a polyanhydride; a polyorthoester; a polyetherester; a polycaprolactone; a polyesteramide; a block copolymer of polyethylene glycol and lactide or glycolide; and a blend or copolymer thereof.

12. The pharmaceutical formulation of Claim 11, wherein the polymer is a poly(lactide-co-glycolide) polymer.

13. The pharmaceutical formulation of Claim 6, wherein the biologically active agent is a polypeptide.

14. The pharmaceutical formulation of Claim 11, wherein the polypeptide is selected from the group consisting of a growth hormone, a hepatocyte growth factor (HGF), a vascular endothelial growth factor (VEGF), an anti-vascular endothelial growth factor Fab (anti-VEGF Fab), a glucagon-like peptide I (GLP-I), a nerve growth factor, and an insulin-like growth factor.

15. The pharmaceutical formulation of Claim 6, wherein the concentration of the polymeric matrix comprising the biologically active agent is between at least about 1 mg/mL to about 500 mg/mL of formulation.

16. The pharmaceutical formulation of Claim 15, wherein the concentration of the polymeric matrix comprising the biologically active agent is between at least about 1 mg/mL to about 300 mg/mL of formulation.

17. A pharmaceutical formulation comprising:
- (a) particles comprising a biocompatible polymeric matrix comprising a poly(lactide-co-glycolide) polymer;
 - (b) an effective amount of a biologically active polypeptide dispersed within the polymeric matrix; and
 - (c) an injection vehicle comprising hyaluronic acid or a derivative thereof.
18. A method for producing a pharmaceutical formulation comprising:
- adding an effective amount of a biologically active agent in particulate form or coated on, dispersed within, or accompanied by particles
 - to an injection vehicle comprising hyaluronic acid or a derivative thereof.
19. The method of Claim 18 wherein the injection vehicle comprises hyaluronic acid.
20. A method for administering a pharmaceutical formulation of Claim 17 comprising injecting the pharmaceutical formulation through a 23-gauge or smaller needle.

add B3/
add B2/
add B1/